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Abstract
Background: Hepatitis B virus (HBV) can have mutations that include the a determinant, which causes
breakthrough infection. In particular, a single mutation at amino acid 145 of the surface protein (G145) is frequently
reported in the failure of prophylactic treatment. The aim of this study was to evaluate the frequency of the a
determinant mutants, especially the G145 variant, in Japan, where universal vaccination has not been adopted.
Methods: The present study was a retrospective study. The study cohorts were defined as follows: group 1,
children with failure to prevent mother-to-child transmission despite immunoprophylaxis (n = 18, male/female = 8/
10, age 1-14 years; median 6 years); group 2, HBV carriers who had not received vaccination or hepatitis B
immunoglobulin (n = 107, male/female = 107, age 1-52 years; median 16 years). To detect the G145R and G145A
mutants in patients, we designed 3 probes for real-time PCR. We also performed direct sequencing and cloning of
PCR products.
Results: By mutant-specific real-time PCR, one subject (5.6%) was positive for the G145R mutant in group 1, while
the G145 mutant was undetectable in group 2. The a determinant mutants were detected in one (5.6%) of the
group 1 subjects and 10 (9.3%) of the group 2 subjects using direct sequencing, but direct sequencing did not
reveal the G145 mutant as a predominant strain in the two groups. However, the subject who was positive
according to the mutant-specific real-time PCR in group 1 had overlapped peaks at nt 587 in the
electropherogram. In group 2, 11 patients had overlapped peaks at nt 587 in the electropherogram. Cloning of
PCR products allowed detection of the G145R mutant as a minor strain in 7 (group 1: 1 subject, group 2: 6
subjects) of 12 subjects who had overlapped peaks at nt 587 in the electropherogram.
Conclusions: The frequency of the a determinant mutants was not high in Japan. However, the G145R mutant
was often present as a minor population in children and adults. HBV carriers might have the a determinant
mutants as a minor form.
Background
Hepatitis B virus (HBV) variants with mutations in the a
determinant frequently emerge under immunological
pressure induced by the HB vaccine or HB immunoglo-
bulin (HBIG)[1-4]. Although the mechanism of the
emergence of a determinant mutants remains unclear,
preexisting mutants as a minor population or as the pre-
dominant population could survive, replicate, and cause
a breakthrough infection after the host receives the HB
vaccine or HBIG. Japan continues to implement an
HBV immunization strategy that targets high-risk
groups rather than instituting a universal vaccination
program. There is no immune pressure induced by uni-
versal vaccination, and thus knowing the prevalence of
mutants in Japan will be useful for clarifying the
mechanism of the emergence of mutants.
Of various mutants with the a determinant, the
mutant with a single mutation at the 145th amino acid
of the hepatitis B surface antigen (HBsAg) has been fre-
quently reported to cause the failure of prophylaxis in
mother-to-child transmissio n[ 5 - 1 0 ] .T h u s ,i ti si n d i s -
pensable to clarify the frequency of the a determinant
mutants when developing the future vaccine strategy in
Japan. The aim of this study was to evaluate the fre-
quency of the a determinant mutants in HBV carriers.
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minor strain. Mutant-specific real-time polymerase
chain reaction (PCR) and direct sequencing were per-
formed. Moreover, cloning of PCR products was used to
investigate the presence of the G145variant as a minor
strain.
Methods
Patients
The present study was a retrospective study. The study
cohorts consisted of the following two groups: group 1,
children with failure to prevent mother-to-child trans-
mission despite prophylaxis; group 2, HBV carriers who
had not received the HB vaccination or HBIG. A total
of 18 children (male/female = 8/10, age: 1-14 years,
median 6, genotype A/B/C = 0/0/18) were referred to
our institute to failure of prophylactic treatment with
the HB vaccine or HBIG in mother-to-child transmis-
sion. They belonged to the failure of prophylactic treat-
ment group (group 1). A total of 107 chronically
infected patients (male/female = 47/60, age: 1-9 years; n
= 19, age 10-19 years; n = 54, age: 20-52 years; n = 34,
genotype A/B/C = 1/14/92) were followed in our insti-
tute. They had no history of receiving the HB vaccine or
HBIG. These subjects belonged to group 2. The patients’
characteristics by group are shown in Table 1. Informed
written consent for study participation was obtained
from all patients or their parents. The study protocol
was approved by the ethics committees of Yokohama
Eastern Hospital.
HBV DNA extraction and quantification of HBV DNA in
serum
HBV DNA was extracted from 200 μL of serum using
QIAamp DNA Blood Mini kit (QIAGEN, Hilden, Ger-
many). The real-time PCR was performed for quantifica-
tion using the genotype-independent real-time PCR
method described previously [11]. The PCR assay was
performed in a MX3000P (Stratagene), and the results
were analyzed with MxPro software (version 3.0). The
lower detection limit was > 100 copies/mL. All assays
were carried out in duplicate with negative control
samples.
Real-time PCR for the G145R and G145A mutants
To detect the G145R and G145A mutants as minor
strains in patients, we designed 3 probes based on the
sequences of the G145R and G145A mutants [12]. The
primers used were 5’-GAT TCC TGC TCA AGG AAC
CTC-3’ (forward; nt 529-549) and 5’-CGA AAG CCC
AGG ATG ATG-3’ (reverse; nt 612-629). The point
mutation at nt 587 (G145R, mutant 1: G to A, mutant
2: G to C) and nt 588 (G145A, mutant 3: G to C) were
applied to the sequence of the probes. The following
probes (nt 571-591) were used for mutant-specific real-
time PCR: wild type: 5’-FAM-TACAAAACCTTCG-
GACGGAAACTGC-TAMRA-3’;m u t a n t1 :5 ’-FAM-
TACAAAACCTTCGGACAGAAACTGC-TAMRA-3’;
mutant 2: 5’-FAM-TACAAAACCTTCGGACC-
GAAACTGC-TAMRA-3’;m u t a n t3 :5 ’-FAM-
TACAAAACCTTCGGACGCAAACTGC-TAMRA-3’.
Nucleotide positions were designated on the basis of
nucleotide sequences from genotype C (GenBank/EMBL
accession number AB300361). PCR was performed in a
50-μL reaction mixture containing 25 μLT a q M a nU n i -
versal PCR master mix (Applied Biosystems) with 0.2
μM primers, 0.1 μM probes, and 10 μL extracted DNA.
The PCR program consisted of an initial pre-cycle incu-
bation at 50°C for 2 min and 95°C for 10 min, followed
by 50 cycles of 95°C for 15 s and 60°C for 1 min. All
assays were carried out in duplicate with negative con-
trol samples.
Sequencing and cloning
All HBV DNA samples were amplified by nested PCR
using 2 primer pairs with sequences corresponding to
the surface region of the HBV genome, which encom-
passed a determinant region. We used the following pri-
mers: outer sense: ACAGAGTCTAGACTCGTGGT (nt
241-260); outer antisense: AAAGCCCTACGAAC-
CACTGA (nt 694-713); inner sense: GGACTTCTCT-
CAATTTTCTAGGG (nt 261-283); inner antisense:
Table 1 Patient characteristics by group
Failure of prophylactic treatment for mother-to-child
transmission
Chronic HBV infection without HBIG or HB
vaccine
n = 18 n = 107
Gender, male/female 8/10 47/60
Age 1-14 yr. (median, 6) 1-52 yr. (median, 16)
Genotype A/B/C 0/0/18 1/14/92
HBeAg (mother) 16 (15, 3 unknown) 60
HBV DNA levels in blood, log
copies/mL
5.6 - > 8.8 (median, 8.6) 2.1 - > 8.8 (median, 4.9)
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Amplification was performed by nested PCR in a 50-μl
reaction mixture containing 25 pmol of each primer and
2.5 U of Taq DNA polymerase (TaKaRa Ex Taq, Takara
Bio, Shiga, Japan). The first round of amplification was
performed for 35 cycles (denaturation at 94°C for 30 s,
annealing at 55°C for 30 s, and extension at 72°C for 1
min) with the external primers. In the second round of
PCR, 1 μM of the first-round PCR products was sub-
mitted to a second round of PCR using the internal pri-
mers. The second-round PCR program was the same as
that for the first round. PCR products were cloned and
sequenced using a TOPO TA cloning kit for sequencing
(Invitrogen, Carlsbad, CA). DNA sequences were deter-
mined using the Applied Biosystems 3730xl DNA Ana-
lyzer (Applied Biosystems, Foster City, CA).
Results
Sensitivity of mutant-specific real-time PCR
We evaluated the sensitivity and specificity of mutant-
specific real-time PCR (Figure 1). HBV DNA from clini-
cal serum samples in which we had confirmed a muta-
tion with G145R (at nt 587 G to A, genotype C, the
levels of HBV DNA: 5.7 log copies/mL) was amplified
using the mutant-specific real-time PCR in duplicate.
The amplification signals were detected for HBV DNA
from serum with mutant G145R in the wild probe and
the mutant probe. However, cycle threshold (Ct) values
in the mutant probe (mutant 1, Ct values = 26.42 and
26.57) were lower than those in the wild probe (Ct
values = 27.76 and 27.99), as shown Figure 1A. In addi-
tion, the amplification curves in the mutant 1 probe
showed a steeper upward slope. Although the mutant
primer detected a weak signal of wild-type HBV DNA,
these findings suggested that the mutant primer could
clearly identify the mutant with a point mutation at nt
587 G to A if the mutant was the predominant strain.
Next, we assessed whether the specific probe could
distinguish the G145R mutant as a minor strain from
the predominant wild-type strain (Figure 1B-C). Con-
structed plasmid mutant-type (a point mutation at nt
587 G to A) DNA and wild-type DNA were mixed. The
results of real-time PCR using 4 probes for mixed DNA
at mutant:wild ratios of 1:1, 1:10, and 1:100 are shown
in Figures 1B-C, and 1D, respectively. At the 1:1 ratio,
the amplification curve of the mutant 1 probe showed
the same Ct values and similar steep slopes (wild-type:
Ct values = 24.53 and 24.71; mutant 1: Ct values =
24.86 and 24.27) (Figure 1B). At the 1:10 ratio, however,
the amplification curve of the mutant probe showed a
less steep upward slope compared to that of the wild-
type probe, and the Ct values were greater (wild-type:
Ct values = 24.52 and 24.76; mutant 1: Ct values =
26.60 and 27.27; mutant 2: Ct values = 27.61 and 27.89;
mutant 3: Ct values = 27.58 and 28.36) (Figure 1C). At
the 1:100 ratio, there was no difference in the Ct values
or in the shape of the amplification curves among these
mutant-specific probes, and it was impossible to identify
t h em u t a n tw i t hap o i n tm u t a t i o na tn t5 8 7Gt oA
(wild-type: Ct values = 24.74 and 24.91; mutant 1: Ct
values = 27.65 and 27.75; mutant 2: Ct values = 28.04
and 28.12; mutant 3: Ct values = 26.95 and 27.17) (Fig-
ure 1D). These findings suggested that the mutant
probe could detect the G145R mutant representing as
little as 10% of the wild-type population. Therefore, if
the Ct value in a mutant-type probe was the same as or
lower than that in the wild-type probe, the sample was
considered to be positive for the mutant-specific real-
time PCR.
Positive rate of mutant-specific real-time PCR
Chronically infected children despite receiving
immunoprophylaxis
The emergence of mutants is a well-known cause of the
failure of immunoprophylactic treatment for mother-to-
child transmission of HBV. Of the 18 children chroni-
cally infected despite receiving immunoprophylaxis, one
(5.6%), a 10-year-old girl, was positive for the mutant-
specific real-time PCR using the mutant 1 probe (Table
2). This child was also positive for the wild-type probe
(Figure 2A).
HBV carriers without HBIG or the HB vaccine
We examined 107 HBV carriers who had never received
HBIG or the HB vaccine and found that none of them
w a sp o s i t i v ef o rt h em u t a n t - s p e c i f i cr e a l - t i m eP C R
(Table 2). The primers of the mutant-specific real-time
PCR did not work in a patient infected with genotype A.
Genotype from D to H were not available in this study.
Direct sequencing
To confirm the results of the mutant-specific real-time
PCR, we performed direct sequencing. Although the girl
with failure of immunoprophylaxis was positive for the
mutant 1 probe, the G145R mutant was not detected as
a predominant strain in any patients (Table 2). In addi-
tion to the G145R mutant, the a determinant (aa 124-
147) was evaluated using the direct sequencing. As a
predominant strain, I/T126S mutant was detected in
one (5.6%) of the 18 children with failure of prophylaxis.
In addition, I/T126S (n = 4), I/T126V (n = 1), Q129L (n
= 1), T131P (n = 2), M133T + T140I (n = 1), and
S136Y (n = 1) mutants were detected as a predominant
strain in 10 (9.3%) of the 107 HBV carriers who had not
received the HB vaccine or HBIG.
Detection of G145R mutant by cloning of PCR products
The mutant-specific real-time PCR (mutant 1 probe)
could detect the G145R mutant in a child with failure of
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indicated that the G145R mutant strain and wild-type
strain were coexisting (Figure 2A, upper, the serum
sample was taken in May 2007). Consistent with the
results of the mutant-specific real-time PCR, her electro-
pherogram indicated that the wild-type HBV was the
predominant strain and the G145R mutant was a minor
strain. Of the 20 clones, 5 (25.0%) were G145R mutants
(Figure 2A, lower) by PCR cloning technique. This find-
ing suggested that the mutant-specific real-time PCR
had the ability to detect 25% of minor strains in HBV
populations. The girl was positive for HBeAg. Her
serum ALT values had been elevated to twice the nor-
mal values for 6 years, and the levels of HBV DNA in
her blood were more than 7 log copies/ml. She had
received antiviral therapy (entecavir, 0.5 mg/day) for 48
Mutant 1
Wild-type
Mutant 1
Wild-type
Wild-type
Mutant 1
(A) (B)
(C) (D)
Wild-type
Mutant 1
Negative 
control
Mutant 2
Mutant 3
Mutant 2
Mutant 3
Mutant 2, 3
Mutant 2, 3
Wild-type :Mutant=1:1
Wild-type :Mutant=10:1 Wild-type :Mutant=100:1
Figure 1 Mutant-specific real-time PCR was performed in duplicate for each probe.( A)H B VD N Af r o ms e r u mw i t ha ne s c a p em u t a n t
(single mutation at nt 587, A to G) was amplified using the wild-type and mutant 1, 2, and 3 probes. (B) Constructed plasmid mutant-type
(single mutation at nt 587 G to A) DNA and wild-type DNA were mixed. The amount of the mutant-type plasmid DNA was equal to that of the
wild-type DNA. The curves of the amplification plots are indicated by arrows. (C) Constructed plasmid mutant-type (single mutation at nt 587 G
to A) DNA and wild-type DNA were mixed. The mutant:wild ratio in plasmid DNA was 1:10. (D) Constructed plasmid mutant-type (single
mutation at nt 587 G to A) DNA and wild-type DNA were mixed. The mutant:wild ratio in plasmid DNA was 1:100.
Table 2 Frequency of nt 587 G to A (aa 145 Gly to Arg) mutants
no./total no.
Failure of prophylactic treatment for mother-to-child
transmission
Chronic HBV infection without HBIG or HB
vaccine
Mutant specific real time PCR 1/18 (5.6) 0/107
Direct sequencing (major
clone)
0/18 0/107
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become negative for serum HBV DNA by the comple-
tion of the therapy. 4 months after the completion of
the therapy, however, serum HBV DNA became detect-
able. The mutant-specific real-time PCR and PCR clon-
ing were performed again (Figure 2B, upper, the serum
sample was taken in May 2009), and she was found to
be positive for serum HBV DNA. PCR cloning revealed
that 6 (33.3%) of 18 clones were G145R mutants (Figure
2B, lower).
The result of the PCR cloning for the G145R mutant
in the girl with failure of immunoprophylaxis raised a
question. In her sequence electropherogram, a larger
peak and a smaller peak overlapped at nt 587 of HBsAg
(Figure 2). The larger peak and the smaller peak were
considered to represent the predominant strain and the
minor strain, respectively. This finding suggested that
the electropherogram could be useful for the detection
of minor populations, so we investigated whether clon-
ing of PCR products was more sensitive than mutant-
specific real-time PCR for the detection of minor popu-
lations. Of all the patients in groups 1 and 2, 12 (group
1: F-16, group 2: CHB-2, -5, -26, -30, -42, -62, -67, -73,
-94, -100, and -104) had overlapped peaks at nt 587 in
the electropherogram. We thus performed cloning of
PCR products in all of these patients except for F-16.
Ten or more clones were sequenced. Of the 11 patients,
6 (CHB-26, -62, -67, -73, -94, and -104) had the G145R
No. of clone; mutant/wild, 5/20 No. of clone; mutant/wild, 6/18
(A)( B)
Mutant 1 probe
Wild-type probe
Mutant 1 probe
Wild-type probe
nt 587 nt 587
Mutant 3
Mutant 2
Figure 2 Serum HBV DNA from a girl who became positive for HBsAg and negative for anti-HBs despite immunoprophylaxis was
amplified by mutant-specific real-time PCR in duplicate.( A) Before antiviral therapy (May 2007), the Ct values of the amplification plots in
the mutant 1 probe were the same as those for the wild-type probe. In addition, the amplification plots of both probes were similar in the
upward slopes. Although the signals of the mutant 2 and 3 probes were detectable, the curves of the amplification plots were not steep. There
was an overlapped peak at nt 587 in the electropherogram. The larger peak was G, and the smaller peak was A. Of the 20 clones, 5 had a
mutation at nt 587 from G to A. (B) At the cessation of antiviral therapy (May 2009), the girl was negative for serum HBV DNA by real-time PCR.
4 months after the completion of antiviral therapy, however, she became positive again for serum HBV DNA. The signals of the mutant 1 probe
as well as the wild-type probe were detected in the amplification plots (the mutant 2 and 3 probes were not used). The curves of the
amplification plots were steep. There was an overlapped peak at nt 587 in the electropherogram. Of the 18 clones, six had a mutation at nt 587
from G to A.
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jects were HBV carriers with no history of HBIG or the
HB vaccine. Of the 7 HBV carriers with the G145R
mutant, including the girl with failure of immunopro-
phylaxis (F-16), 6 were positive for HBeAg (Table 3,
upper). The remaining 5 patients (CHB-2, -5, -30, -42,
a n d- 1 0 0 ) ,w h oh a do v e r l a p p e dp e a k sa tn t5 8 7b y
sequencing, did not have the G145R mutant as a minor
strain (Table 3, lower).
Discussion
In this study, the a determinant mutants were detected
as predominant strains by direct sequencing in 9.3% of
chronic hepatitis B patients who had not received the
HB vaccine or HBIG.. This figure was comparable with
that reported in a previous study (7.8%), which was con-
ducted in Taiwan before the introduction of universal
vaccination [13,14]. This finding indicates that the pre-
sence of the a determinant mutants was not common in
Japanese children. However, previous studies showed a
higher prevalence rate of the a determinant mutants in
Japan. Ogura et al. reported that the a determinant
mutants were detected in 24% (10/42) of unselected
Japanese HBV carriers [15]. In addition, Takahashi et al.
reported that 48% (19/40) of HBs-positive hepatocelluar
carcinoma patients had the a determinant mutants in
Japan [16]. Apart from Japan, Avellon et al. reported
that the a determinant mutants were detected in 39%
(106/272) of unselected carriers in Spain [17]. that HBV
carriers. Presumably, the age (duration of infection), the
degree of chronic hepatitis, and immunological selection
by vaccine might have influenced the emergence of
mutants. For instance, after the introduction of universal
vaccination in Taiwan, the prevalence of the a determi-
nant mutants was slightly increased and remained
approximately 20% between 1989 and 2004 [13,14].
Direct sequencing showed that I/T126S [9,18,19], I/
T126V [16], Q129L [20,21], T131P [22], M133T +
T140I [13,14,21,23], and S136Y [24,25] mutants were
present as a predominant strain in 107 HBV carriers.
All of these mutants were reported in previous studies,
but the pathogenicity of I/T126V, Q129L, T131P has
not been confirmed. Among these mutants, the I/T126S
mutant was the most frequent (4/107 = 4.7%) in the
group 2 of the present study. Moreover, the I/T126S
mutant was detected in a child with the prophylactic
failure in group 1. In the previous study targeting unse-
lected Spanish carriers, the prevalence rate of the I/
T126S mutant was 0.4% (1/272)[17]. Compared with the
previous study, the frequency of I/T126S of the present
study is high. The I/T126S mutant has been frequently
o b s e r v e di nt h es t u d i e sf r o mJ a p a n ,i n1 2 %( 5 / 4 2 )[ 1 5 ]
and 13% (5/40)[16] of adult HBV carriers. In contrast, a
mutation at the 127th amino acid of the hepatitis B sur-
face antigen (genotype A:5.9%, genotype D: 8.8%) was
t h em o s tf r e q u e n t l yr e p o r t e dm u t a t i o ni naS p a n i s h
study [17]. Genotypes A and E are predominant in Eur-
ope, whereas genotypes B and C prevail in Southeast
Asia, including Japan. There is a possibility that the dif-
ference among HBV genotype could be associated with
the frequency of the I/T126S mutant.
Before the present experiment was performed, we pre-
dicted that the mutant-specific real-time PCR technique
w o u l db ea b l et om o r ef r e q u e n t l yd e t e c tt h eG 1 4 5
mutant compared with sequencing and cloning. Using
the constructed plasmid, the mutant-specific probe
could detect 10% of mutants among wild-type virus in
this study. Similarly, Zhang et al. reported that the real-
time PCR method could detect 5% of mutants among
wild-type virus [12]. The present study showed that the
mutant-specific real-time PCR identified a child in
whom the G145R mutant and wild-type virus were
Table 3 Results of PCR cloning in patients who had overlapped peaks (G and A) at nt 587 in the electropherogram
Patint ID. age (yr.) HBsAg HBeAg HBV DNA in blood, log copies/mL no./total no.
Wild-type Mutant-type (%)
F-16 10 positive positive 5.2 15/20 5/20 (25)
CHB-26 12 positive positive 6.9 12/14 2/14 (14)
CHB-62 15 positive negative 2.3 13/15 2/15 (13)
CHB-67 13 positive positive 4.1 24/25 1/25 (4)
CHB-73 43 positive positive 5.2 14/16 2/16 (13)
CHB-94 10 positive positive 7.4 14/15 1/15 (7)
CHB-104 40 positive positive > 8.8 15/16 1/16 (6)
CHB-2 7 positive negative 2.1 16/16
CHB-5 14 positive positive 4.9 30/30
CHB-30 43 positive positive 5.3 14/14
CHB-42 24 positive positive 8.7 28/28
CHB-100 42 positive positive 6.3 30/30
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clones was 5 (25%) out of 20 clones. These findings
proved that the mutant-specific probe could detect a
minor mutant-type virus among viral populations in a
clinical sample. However, we found that sequencing and
c l o n i n gw e r em o r es e n s i t i v et h a nt h em u t a n t - s p e c i f i c
real-time PCR, although performance of these techni-
ques required more time. Sequencing and cloning could
detect much smaller populations of mutant-type virus,
ranging from 6% to 14% of subpopulations in this study.
If cloning of PCR products is carefully performed in
every nucleotide of the a determinant, the prevalence of
finding the a determinant mutant will be increased.
Therefore, the a determinant mutant is present as a
minor population in a high proportion of HBV carriers.
This notion is consistent with the fact that selection
immunological pressure such as the HB vaccine and
HBIG allows the minor a determent mutant to become
the predominant strain of the virus.
The virulence of the G145R mutant is indeterminate.
The results of previous studies suggested that the
G145R mutation reduced the ability of viral assembly
and secretion [26,27]. In this study, however, the levels
of serum transaminases had been elevated and the
levels of HBV DNA had remained high for several
years in the girl infected with the G145R mutant,
which was detected by the mutant-specific real-time
PCR. The levels of HBV DNA in the blood were not
significantly lower in patients with the G145R mutant
than in patients without the G145R mutant (data not
shown). Although the G145R mutant was mixed with
the predominant wild-type virus and viral replication
was influenced by pre-core and basal core promoter
mutation, these findings suggest that infection with the
G145R mutant does not always promise a good prog-
nosis. After treatment with entecavir, the G145R
mutant as well as the wild-type virus appeared again in
the girl.
Of the 18 the children with prophylactic failure in the
present study, one had an a d e t e r m i n a n tm u t a n t( I /
T126S) as a predominant strain and one had an a deter-
minant mutant (G145R) as a minor strain. This finding
was consistent with previous studies [5,28,29]. The
detection rate of a determinant mutation varied from
12% to 26% in children with prophylactic failure, indi-
cating that the main cause of failure to prevent mother-
to-child transmission was not the emergence of a deter-
minant mutants. Recent studies suggest that high viral
load in blood is closely related to the failure of prophy-
laxis with vaccine and HBIG [30-32].
Conclusions
The a determinant mutants were not the predominant
mutations in Japan. However, the G145R mutant was
present as a minor population in children and adults.
Numerous a determinant mutants could be lost in the
mass of the wild-type virus.
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